Semaglutide reduced weight and cardiovascular events in three trials

What evidence supports semaglutide?

Three registrational Phase 3 randomized trials, all published in the New England Journal of Medicine, anchor semaglutide's evidence: STEP 1 for weight, and SUSTAIN-6 and SELECT for cardiovascular outcomes. Each gives strong, direct trial evidence for a different claim.

STEP 1 tested weight reduction in adults without diabetes ^[1]. SUSTAIN-6 tested cardiovascular outcomes in type 2 diabetes ^[2]. SELECT, the newest layer, tested cardiovascular outcomes in obesity without diabetes ^[3].

Outside those three results, claims about titration schedules, durability off the drug, muscle loss and compounded products rest on mechanism or remain unstudied in these trials. The distinction matters.

How does semaglutide work?

Semaglutide is a 31-amino-acid analog of human GLP-1 (glucagon-like peptide-1), modified with a C18 fatty-diacid chain that binds circulating albumin. Albumin binding is the whole trick behind once-weekly dosing: it slows renal clearance and gives semaglutide a half-life long enough for weekly injections to maintain steady receptor engagement. Native GLP-1 has a half-life of minutes.

As a GLP-1 receptor agonist, semaglutide acts on receptors in the pancreas, augmenting glucose-dependent insulin release, and in the stomach, slowing gastric emptying, which prolongs satiety after meals. It also acts in the hypothalamus, where GLP-1 receptor activity is linked to appetite regulation. Slower gastric emptying plus central appetite signaling is the mechanistic basis for reduced caloric intake, and that part of the story is well established pharmacology.

The oral formulation, marketed as Rybelsus, co-formulates semaglutide with SNAC, an absorption enhancer. SNAC transiently raises local stomach pH and protects the peptide from proteolytic degradation long enough for a fraction to cross the gastric mucosa. Rybelsus is the same molecule delivered a different way, engineered around the basic problem that peptides do not survive oral administration intact. Why oral semaglutide tablets need such large doses follows that problem through.

How much weight did semaglutide produce in STEP 1?

Semaglutide produced a mean 14.9% weight loss at 68 weeks in STEP 1, versus 2.4% on placebo (P<0.001) ^[1]. The trial randomized 1,961 adults with overweight or obesity and no diabetes to 2.4 mg semaglutide weekly or placebo ^[1].

STEP 1 is a large, well-powered, randomized, placebo-controlled result, as close to proven as peptide efficacy claims get. Its injectable dosing ladder titrated to a maintenance dose of 2.4 mg once weekly, the target dose associated with the ~15% weight-loss result ^[1].

The mean hides variance. In STEP 1, 86.4% of participants lost at least 5% of body weight ^[1], which means roughly one in seven did not clear even that modest bar.

Slower or faster titration schedules from forum protocols or compounding sources have not been tested head-to-head against the studied schedule in these trials.

Does semaglutide reduce cardiovascular events in type 2 diabetes?

Yes: in SUSTAIN-6, semaglutide reduced the composite of cardiovascular death, nonfatal heart attack or nonfatal stroke, with event rates of 6.6% versus 8.9% and a hazard ratio of 0.74 ^[2]. The trial randomized 3,297 people with type 2 diabetes at elevated cardiovascular risk ^[2].

SUSTAIN-6 was designed as a noninferiority safety trial and ended up showing a superiority signal. Regulators generally treat that combination cautiously, but it is a real finding from a large randomized dataset.

Does semaglutide reduce cardiovascular events in people without diabetes?

Yes: in SELECT, semaglutide reduced major adverse cardiovascular events (MACE) to 6.5% versus 8.0% on placebo, a hazard ratio of 0.80 (P<0.001) ^[3]. SELECT enrolled 17,604 adults with pre-existing cardiovascular disease and overweight or obesity but no diabetes, and followed them for a mean of 39.8 months ^[3].

SELECT reframes semaglutide as a drug whose benefit is not solely downstream of glucose control or weight loss. The cardiovascular effect showed up even in people who were not diabetic.

What side effects does semaglutide cause?

Gastrointestinal effects, including nausea, vomiting, diarrhea and constipation, are semaglutide's most commonly reported adverse events during titration. That pattern fits a mechanism that deliberately slows gastric emptying.

Semaglutide carries a boxed warning for thyroid C-cell tumors based on a rodent signal. The human relevance of that finding is unresolved: the signal comes from rodents and is not a demonstrated human risk.

Does the weight stay off after stopping semaglutide?

Much of it does not: STEP 1's off-drug extension period reported substantial regain after discontinuation. None of the three trials was designed to answer what happens after people stop.

The regain is consistent with semaglutide's mechanism. Remove a receptor agonist, and the appetite-suppressing and gastric-emptying effects it was producing go with it.

Treat any weight-loss number from these trials as a snapshot taken while participants remained on active drug, not a stable, permanent outcome. What happens when people come off a GLP-1 covers the withdrawal evidence.

Is compounded semaglutide the same as the prescription drug?

Unknown, because no regulatory requirement makes research-use-only or compounded semaglutide match the prescription product. Prescription semaglutide goes through manufacturing controls that establish purity, concentration accuracy and a defined degradation profile before it reaches a patient. Research-use-only material carries none of that as a regulatory requirement.

Peptide-forum culture consistently underweights this gap. No published, citable adverse-event dataset exists for that supply chain comparable to the one for the trial-tested product. That is not a vague safety warning; it is a literal absence of the kind of evidence behind the trial results.

Reported issues from self-drawn multidose vials and dosing errors are a different risk category from anything measured in STEP 1, SUSTAIN-6 or SELECT. Nothing in the evidence base supports treating the two supplies as pharmacologically interchangeable.

What is still unknown about semaglutide's long-term effects?

Semaglutide's safety beyond about 3.3 years and its effect on muscle mass are both unsettled:

• Safety beyond the trial window. SELECT's 39.8-month mean follow-up ^[3] is the longest human safety window among the three trials. That is meaningful, but it is not decades. Anyone assuming proven long-term safety past three to four years is extrapolating, not citing.
• Muscle mass. The broader evidence on this drug class describes muscle loss as a nontrivial fraction of total weight lost during rapid reduction, an expected consequence of any large, fast caloric deficit regardless of the tool producing it. Assume some proportion of any weight-loss figure is lean mass until composition data specific to your situation say otherwise. The evidence on GLP-1 muscle loss puts numbers on that proportion.